表紙
市場調査レポート

PharmaPoint:髄膜炎菌ワクチン - 世界の医薬品の予測と市場分析

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 289835
出版日 ページ情報 英文 424 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
PharmaPoint:髄膜炎菌ワクチン - 世界の医薬品の予測と市場分析 PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025
出版日: 2016年05月24日 ページ情報: 英文 424 Pages
概要

当レポートでは、世界の髄膜炎菌ウイルス市場の現状と将来展望について分析し、疾患の概要や今後の疫学的予測、主要国での予防体性、主要企業のプロファイルと代表的製品、市場のアンメットニーズと将来的な機会、現在治験中のパイプライン製品の情報、今後の市場規模と影響要因などを調査しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • イントロダクション
  • 病因と病態生理学
  • 症状
  • 予後

第4章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 米国
    • 欧州主要5ヶ国
    • 日本・ブラジル
  • 予測手法
  • 髄膜炎菌性疾患の疫学的予測(今後11年間分)
  • 議論

第5章 疾患の管理

  • 髄膜炎菌の予防政策
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • ブラジル

第6章 競合環境

  • 概要
  • 製品プロファイル - MenACWYワクチン
    • Menactra
    • Menveo
    • Nimenrix
  • 製品プロファイル - MenBワクチン
    • Bexsero
    • Trumenba
  • 製品プロファイル - MenCワクチン
    • NeisVac-C
    • Menjugate
    • Menitorix
  • その他の髄膜炎菌ワクチン

第7章 アンメットニーズと市場機会

  • 概要
  • 一般的な髄膜炎菌ワクチンの安全性と効果
  • 侵襲性髄膜炎菌に対する長期的予防性
  • 治験設計における改善
  • コスト効率が高いワクチン
  • 妊婦向け髄膜炎菌ワクチン
  • 乳幼児期におけるワクチン接種の減少
  • 一般に対する教育と認知の強化

第8章 パイプライン評価

  • 概要
  • 治験マッピングと将来動向
  • 治験中の有望なワクチン
  • 治験の初期段階にある有望なワクチン

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の概要
  • 企業プロファイル
    • GlaxoSmithKline
    • Sanofi
    • Pfizer

第10章 市場の見通し

  • 世界市場
    • 市場予測
    • 市場促進・阻害要因:世界的課題
  • 米国
  • 欧州5カ国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
  • 日本
  • ブラジル

第11章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC115PIDR

Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of all cases still result in death within 24 to 48 hours of symptom onset. This rapid onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.

Pharmaceutical companies have developed vaccines addressing the most urgent medical needs based on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories include monovalent vaccines targeting serogroup C (MenC vaccines), vaccines protecting against most serogroup B strains (MenB vaccines), and tetravalent vaccines protecting against serogroups A, C, W, and Y (MenACWY vaccines). While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the various serogroups.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the meningococcal vaccine marketplace.
  • What will be the effect of recent and upcoming changes in national immunization schedules?
  • How will the new first-in-class vaccine covering all main serogroups (MenABCWY) be received in the different markets?
  • What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
  • Which patient population(s) are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?

Key Findings

  • GlobalData projects the meningococcal vaccine market in the US, 5EU, Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Further growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil and Japan will experience a decline at a negative CAGR of 1.8% and 0.9% respectively.
  • With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the major unmet need to be addressed in the oncoming years.
  • GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.

Scope

  • Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution, as well current routine meningococcal vaccine recommendations of all 8MM covered.
  • Topline meningococcal vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global meningococcal vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 11

  • 1.1 List of Tables 18
  • 1.2 List of Figures 24

2 Introduction 26

  • 2.1 Catalyst 26
  • 2.2 Related Reports 27
  • 2.3 Upcoming Related Reports 27

3 Disease Overview 28

  • 3.1 Introduction 28
  • 3.2 Etiology and Pathophysiology 29
    • 3.2.1 Etiology 29
    • 3.2.2 Pathophysiology 35
  • 3.3 Symptoms 37
  • 3.4 Prognosis 38

4 Epidemiology 39

  • 4.1 Disease Background 39
  • 4.2 Risk Factors and morbidities 40
  • 4.3 Global Trends 42
    • 4.3.1 US 43
    • 4.3.2 5EU 44
    • 4.3.3 Japan and Brazil 46
  • 4.4 Forecast Methodology 47
    • 4.4.1 Sources Used Tables 48
    • 4.4.2 Forecast Assumptions and Methods 55
    • 4.4.3 Sources Not Used 69
  • 4.5 Epidemiological Forecast for IMD (2015-2025) 70
    • 4.5.1 All IMD Combined 70
    • 4.5.2 Laboratory-Confirmed Incident Cases of Serogroup B IMD 79
    • 4.5.3 Laboratory-Confirmed Incident Cases of Serogroup C IMD 82
    • 4.5.4 Laboratory-Confirmed Incident Cases of Serogroup Y IMD 84
    • 4.5.5 Laboratory-Confirmed Incident Cases of Other Serogroup IMD 86
    • 4.5.6 Distribution of Serogroups 88
    • 4.5.7 US College Freshmen 90
  • 4.6 Discussion 91
    • 4.6.1 Epidemiological Forecast Insight 91
    • 4.6.2 Limitations of the Analysis 93
    • 4.6.3 Strengths of the Analysis 94

5 Disease Management 95

  • 5.1 Meningococcal Immunization Policy 95
    • 5.1.1 Routine Immunization Recommendations and Most Frequently Administered Meningococcal Vaccines 98
  • 5.2 US 101
    • 5.2.1 Immunization Recommendations 103
    • 5.2.2 Clinical Practice 107
  • 5.3 France 109
    • 5.3.1 Immunization Recommendations 110
    • 5.3.2 Clinical Practice 113
  • 5.4 Germany 115
    • 5.4.1 Immunization Recommendations 115
    • 5.4.2 Clinical Practice 118
  • 5.5 Italy 119
    • 5.5.1 Immunization Recommendations 120
    • 5.5.2 Clinical Practice 122
  • 5.6 Spain 122
    • 5.6.1 Immunization Recommendations 123
    • 5.6.2 Clinical Practice 126
  • 5.7 UK 127
    • 5.7.1 Immunization Recommendations 128
    • 5.7.2 Clinical Practice 131
  • 5.8 Japan 132
  • 5.9 Brazil 134
    • 5.9.1 Immunization Recommendations 135
    • 5.9.2 Clinical Practice 137

6 Competitive Assessment 138

  • 6.1 Overview 138
  • 6.2 Product Profiles - MenACWY Vaccines 140
    • 6.2.1 Menactra 140
    • 6.2.2 Menveo 147
    • 6.2.3 Nimenrix 154
  • 6.3 Product Profiles - MenB Vaccines 160
    • 6.3.1 Bexsero 160
    • 6.3.2 Trumenba 169
  • 6.4 Product Profiles - MenC Vaccines 177
    • 6.4.1 NeisVac-C 177
    • 6.4.2 Menjugate 182
    • 6.4.3 Menitorix 188
  • 6.5 Other Meningococcal Vaccines 192
    • 6.5.1 Overview 192

7 Unmet Needs and Opportunities 197

  • 7.1 Overview 197
  • 7.2 A Safe and Effective Universal Meningococcal Vaccine 199
    • 7.2.1 Unmet Need 199
    • 7.2.2 Gap Analysis 200
    • 7.2.3 Opportunity 201
  • 7.3 Long-Term Protection Against Invasive Meningococcal Disease 203
    • 7.3.1 Unmet Need 203
    • 7.3.2 Gap Analysis 203
    • 7.3.3 Opportunity 204
  • 7.4 Improvements in Clinical Trial Design 205
    • 7.4.1 Unmet Need 205
    • 7.4.2 Gap Analysis 207
    • 7.4.3 Opportunity 208
  • 7.5 Improved Vaccine Cost Effectiveness 209
    • 7.5.1 Unmet Need 209
    • 7.5.2 Gap Analysis 210
    • 7.5.3 Opportunity 210
  • 7.6 A Prenatal Meningococcal Vaccine 212
    • 7.6.1 Unmet Need 212
    • 7.6.2 Gap Analysis 212
    • 7.6.3 Opportunity 213
  • 7.7 Reducing Vaccination Frequency in Infants 214
    • 7.7.1 Unmet Need 214
    • 7.7.2 Gap Analysis 215
    • 7.7.3 Opportunity 215
  • 7.8 Enhanced Education and Awareness of the General Population 217
    • 7.8.1 Unmet Need 217
    • 7.8.2 Gap Analysis 218
    • 7.8.3 Opportunity 219

8 Pipeline Assessment 221

  • 8.1 Overview 221
  • 8.2 Clinical Trial Mapping and Future Trends 223
    • 8.2.1 Clinical Trials by Status 223
    • 8.2.2 Clinical Trials by Pipeline Vaccine 224
    • 8.2.3 Future Clinical Trial Design Considerations 225
  • 8.3 Promising Vaccines in Clinical Development 229
    • 8.3.1 MenABCWY 231
    • 8.3.2 Men Quad TT 242
    • 8.3.3 Brazil MenC Vaccine 248
  • 8.4 Promising Early-Stage Pipeline Products 252

9 Current and Future Players 255

  • 9.1 Overview 255
  • 9.2 Trends in Corporate Strategy 261
  • 9.3 Company Profiles 264
    • 9.3.1 GlaxoSmithKline 264
    • 9.3.2 Sanofi 271
    • 9.3.3 Pfizer 275

10 Market Outlook 281

  • 10.1 Global Markets 281
    • 10.1.1 Forecast 281
    • 10.1.2 Drivers and Barriers - Global Issues 288
  • 10.2 United States 296
    • 10.2.1 Forecast 296
    • 10.2.2 Key Events 303
    • 10.2.3 Drivers and Barriers 303
  • 10.3 5EU 309
    • 10.3.1 5EU 309
    • 10.3.2 France 323
    • 10.3.3 Germany 327
    • 10.3.4 Italy 331
    • 10.3.5 Spain 335
    • 10.3.6 UK 340
  • 10.4 Japan 345
    • 10.4.1 Forecast 345
    • 10.4.2 Key Events 348
    • 10.4.3 Drivers and Barriers 349
  • 10.5 Brazil 351
    • 10.5.1 Forecast 351
    • 10.5.2 Key Events 354
    • 10.5.3 Drivers and Barriers 354

11 Appendix 356

  • 11.1 Bibliography 356
  • 11.2 Abbreviations 398
  • 11.3 Methodology 404
  • 11.4 Forecasting Methodology 404
    • 11.4.1 Vaccine Coverage 405
    • 11.4.2 Vaccine Approval vs. Routine Schedule Inclusion 405
    • 11.4.3 Vaccines Included 405
    • 11.4.4 Key Launch Dates 406
    • 11.4.5 General Pricing Assumptions 407
    • 11.4.6 Individual Vaccine Assumptions 408
    • 11.4.7 Pricing of Pipeline Agents 413
  • 11.5 Primary Research - KOLs Interviewed for this Report 414
  • 11.6 Primary Research - Prescriber Survey 419
  • 11.7 About the Authors 420
    • 11.7.1 Analyst 420
    • 11.7.2 Therapy Area Director 420
    • 11.7.3 Epidemiologist 421
    • 11.7.4 Managing Epidemiologist 421
    • 11.7.5 Global Director of Therapy Analysis and Epidemiology 422
    • 11.7.6 Global Head of Healthcare 422
  • 11.8 About GlobalData 423
  • 11.9 Disclaimer 423

List of Tables

1.1 List of Tables

  • Table 1: Symptoms of Meningococcal Disease 38
  • Table 2: Risk Factors and Comorbidities for IMD 41
  • Table 3: 8MM, Sources of Laboratory-Confirmed IMD Incidence 48
  • Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence 49
  • Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence 50
  • Table 6: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence 51
  • Table 7: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W, X, and All Others) 52
  • Table 8: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W IMD Incidence 53
  • Table 9: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence 54
  • Table 10: College Freshmen Residing in Campus Accommodation 54
  • Table 11: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025 71
  • Table 12: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015 73
  • Table 13: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015 74
  • Table 14: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015 76
  • Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025 81
  • Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 83
  • Table 17: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 85
  • Table 18: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 87
  • Table 19: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025 91
  • Table 20: National Immunization Recommendation Agencies, 2016 98
  • Table 21: National Immunization Recommendations for Meningococcal Vaccines, 2016 100
  • Table 22: Most Frequently Administered Meningococcal Vaccines in the Global Markets, 2015 101
  • Table 23: Country Profile - US 103
  • Table 24: Country Profile - France 110
  • Table 25: Country Profile - Germany 115
  • Table 26: Country Profile - Italy 120
  • Table 27: Country Profile - Spain 123
  • Table 28: Country Profile - UK 128
  • Table 29: Country Profile - Japan 134
  • Table 30: Country Profile - Brazil 135
  • Table 31: Leading Vaccines Against Meningococcal Disease, 2015 140
  • Table 32: Product Profile - Menactra 142
  • Table 33: Efficacy of Menactra for Individuals Receiving Either One- or Two-Dose Regimens 144
  • Table 34: Safety of Menactra for Individuals Receiving One Dose of Menactra 145
  • Table 35: Menactra SWOT Analysis, 2016 145
  • Table 36: Global Sales Forecast ($m) for Menactra, 2015-2025 147
  • Table 37: Product Profile - Menveo 149
  • Table 38: Efficacy of Menveo 150
  • Table 39: Safety of Menveo 151
  • Table 40: Menveo SWOT Analysis, 2016 152
  • Table 41: Global Sales Forecasts ($m) for Menveo, 2015-2025 154
  • Table 42: Product Profile - Nimenrix 156
  • Table 43: Efficacy of Nimenrix 157
  • Table 44: Safety of Nimenrix 158
  • Table 45: Nimenrix SWOT Analysis, 2016 159
  • Table 46: Global Sales Forecast ($m) for Nimenrix, 2015-2025 160
  • Table 47: Product Profile - Bexsero 162
  • Table 48: Efficacy of Bexsero 165
  • Table 49: Safety of Bexsero 166
  • Table 50: Bexsero SWOT Analysis, 2016 167
  • Table 51: Global Sales Forecasts ($m) for Bexsero, 2015-2025 169
  • Table 52: Product Profile - Trumenba 171
  • Table 53: Efficacy of Trumenba 173
  • Table 54: Safety of Trumenba 174
  • Table 55: Trumenba SWOT Analysis, 2016 175
  • Table 56: Global Sales Forecasts ($m) for Trumenba, 2015-2025 177
  • Table 57: Product Profile - NeisVac-C 178
  • Table 58: Efficacy of NeisVac-C 179
  • Table 59: Safety of NeisVac-C 180
  • Table 60: NeisVac-C SWOT Analysis, 2016 181
  • Table 61: Global Sales Forecasts ($m) for NeisVac-C, 2015-2025 182
  • Table 62: Product Profile - Menjugate 183
  • Table 63: Efficacy of Menjugate 184
  • Table 64: Safety of Menjugate 185
  • Table 65: Menjugate SWOT Analysis, 2016 186
  • Table 66: Global Sales Forecasts ($m) for Menjugate, 2015-2025 187
  • Table 67: Product Profile - Menitorix 189
  • Table 68: Efficacy of Menitorix 190
  • Table 69: Safety of Menitorix 190
  • Table 70: Menitorix SWOT Analysis, 2016 191
  • Table 71: Global Sales Forecasts ($m) for Menitorix, 2015-2025 192
  • Table 72: Other Meningococcal Vaccines 193
  • Table 73: Unmet Needs and Opportunities for Meningococcal Vaccines 198
  • Table 74: Product Profile - MenABCWY 234
  • Table 75: Immunogenicity of MenABCWY 236
  • Table 76: MenABCWY SWOT Analysis, 2016 240
  • Table 77: Global Sales Forecast ($m) for MenABCWY, 2015-2025 242
  • Table 78: Product Profile - Men Quad TT 243
  • Table 79: Men Quad TT SWOT Analysis, 2016 247
  • Table 80: Global Sales Forecasts ($m) for Men Quad TT, 2015-2025 248
  • Table 81: Product Profile - Brazil's MenC 249
  • Table 82: Brazil MenC SWOT Analysis, 2016 251
  • Table 83: Global Sales Forecast ($m) for Brazil's MenC, 2015-2025 252
  • Table 84: Important Meningococcal Vaccines in Development, 2016 254
  • Table 85: Key Companies in the Meningococcal Vaccine Market in the 8MM, 2016 259
  • Table 86: GSK's Meningococcal Vaccines Portfolio Assessment, 2016 269
  • Table 87: GSK SWOT Analysis in Meningococcal Vaccines, 2016 270
  • Table 88: Sanofi's Meningococcal Vaccines Portfolio Assessment, 2016 274
  • Table 89: Sanofi SWOT Analysis in Meningococcal Vaccines, 2016 275
  • Table 90: Pfizer's Meningococcal Vaccines Portfolio Assessment, 2016 279
  • Table 91: Pfizer SWOT Analysis in Meningococcal Vaccines, 2016 280
  • Table 92: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2015-2025 285
  • Table 93: 8MM Meningococcal Vaccines Market - Drivers and Barriers, 2015-2025 288
  • Table 94: US Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025 301
  • Table 95: Key Events Impacting Sales for Meningococcal Disease in the US, 2015?2025 303
  • Table 96: US Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 303
  • Table 97: 5EU Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025 315
  • Table 98: 5EU Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 317
  • Table 99: France Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025 324
  • Table 100: Key Events Impacting Sales for Meningococcal Vaccines in France, 2015?2025 326
  • Table 101: France Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 326
  • Table 102: Sales Forecast ($m) for Meningococcal Vaccines in Germany, 2015?2025 328
  • Table 103: Key Events Impacting Sales for Meningococcal Disease in Germany, 2015?2025 330
  • Table 104: Germany Meningococcal Vaccines market - Drivers and Barriers, 2015?2025 330
  • Table 105: Italy Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025 332
  • Table 106: Key Events Impacting Sales for Meningococcal Disease in Italy, 2015?2025 334
  • Table 107: Italy Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 334
  • Table 108: Spain Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025 337
  • Table 109: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2015?2025 339
  • Table 110: Spain Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 339
  • Table 111: UK Sales Forecast ($m) for Meningococcal Vaccines, 2015?2025 342
  • Table 112: Key Events Impacting Sales for Meningococcal Disease in the UK, 2015?2025 344
  • Table 113: UK Meningococcal Vaccines market - Drivers and Barriers, 2015?2025 344
  • Table 114: Japan Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025 347
  • Table 115: Key Events Impacting Sales for Meningococcal Vaccines in Japan, 2015?2025 348
  • Table 116: Japan Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 349
  • Table 117: Brazil Sales Forecasts ($m) for Meningococcal Vaccines, 2015?2025 352
  • Table 118: Key Events Impacting Sales for Meningococcal Disease in Brazil, 2015?2025 354
  • Table 119: Brazil Meningococcal Vaccines Market - Drivers and Barriers, 2015?2025 354
  • Table 120: Key Launch Dates 406
  • Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 419

List of Figures

1.2 List of Figures

  • Figure 1: Membrane Structure of N. meningitidis 30
  • Figure 2: Genetic Clusters for Polysaccharide Capsules 32
  • Figure 3: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014 44
  • Figure 4: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025 72
  • Figure 5: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015 75
  • Figure 6: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015 77
  • Figure 7: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015 79
  • Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025 82
  • Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 84
  • Figure 10: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 86
  • Figure 11: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025 88
  • Figure 12: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015 89
  • Figure 13: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025 90
  • Figure 14: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025 91
  • Figure 15: National Immunization Schedule for Meningococcal Vaccines across the 8MM 99
  • Figure 16: Meningococcal Vaccines - Key Clinical Trial Landscape, 2016 224
  • Figure 17: Meningococcal Vaccines - Phase II/III Pipeline, 2016 230
  • Figure 18: Competitive Assessment of Late-Stage Pipeline Meningococcal Vaccines, 2015-2025 231
  • Figure 19: Clinical and Commercial Positioning of MenABCWY 239
  • Figure 20: Clinical and Commercial Positioning of Men Quad TT 246
  • Figure 21: Clinical and Commercial Positioning of Brazil's MenC 250
  • Figure 22: Global Sales of Branded Vaccines for Meningococcal Disease by Company, 2015-2025 260
  • Figure 23: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2015-2025 261
  • Figure 24: Annual Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 286
  • Figure 25: Global Sales for Meningococcal Vaccines by Region, 2015 and 2025 287
  • Figure 26: US Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 302
  • Figure 27: Sales of Meningococcal Vaccines by Type of Vaccine in the 5EU in 2015 and 2025 316
  • Figure 28: France Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 325
  • Figure 29: Germany Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 329
  • Figure 30: Italy Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 333
  • Figure 31: Spain Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 338
  • Figure 32: UK Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 343
  • Figure 33: Japan Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 348
  • Figure 34: Brazil Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025 353
Back to Top